Article Versions Notes

Easaw JC, Lim HJ, Karachiwala H, Gill S, Zhu X, Bateman J. Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology. 2025; 32(11):648. https://doi.org/10.3390/curroncol32110648

Easaw, Jacob C., Howard J. Lim, Hatim Karachiwala, Sharlene Gill, Xiaofu Zhu, and Justin Bateman. 2025. "Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options" Current Oncology 32, no. 11: 648. https://doi.org/10.3390/curroncol32110648

Easaw, J. C., Lim, H. J., Karachiwala, H., Gill, S., Zhu, X., & Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology, 32(11), 648. https://doi.org/10.3390/curroncol32110648